|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 124.12 USD | +0.83% |
|
-11.06% | -12.49% |
| 13/02 | UBS Adjusts Price Target on Neurocrine Biosciences to $161 From $178, Maintains Buy Rating | MT |
| 12/02 | Neurocrine Biosciences' Ingrezza Remains 'Core Value Driver,' Morgan Stanley Says | MT |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | 6.82 | 7.01 | 8.78 | 10.46 | 9.53 | |||||
Return on Total Capital | 7.71 | 8.19 | 10.58 | 12.68 | 11.78 | |||||
Return On Equity % | 7.17 | 10.03 | 12.68 | 14.16 | 16.38 | |||||
Return on Common Equity | 7.17 | 10.03 | 12.68 | 14.16 | 16.38 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 69.79 | 67.29 | 67.96 | 67.52 | 98.18 | |||||
SG&A Margin | 51.46 | 50.56 | 47.04 | 42.76 | 40.42 | |||||
EBITDA Margin % | 19.29 | 17.77 | 22.05 | 25.9 | 23.3 | |||||
EBITA Margin % | 18.33 | 16.76 | 21.11 | 24.91 | 22.39 | |||||
EBIT Margin % | 18.33 | 16.73 | 20.92 | 24.75 | 22.25 | |||||
Income From Continuing Operations Margin % | 7.9 | 10.38 | 13.23 | 14.49 | 16.73 | |||||
Net Income Margin % | 7.9 | 10.38 | 13.23 | 14.49 | 16.73 | |||||
Net Avail. For Common Margin % | 7.9 | 10.38 | 13.23 | 14.49 | 16.73 | |||||
Normalized Net Income Margin | 10.24 | 10.63 | 14.82 | 17.89 | 15.88 | |||||
Levered Free Cash Flow Margin | 21.99 | 15.25 | 21.47 | 19.44 | 9.67 | |||||
Unlevered Free Cash Flow Margin | 21.89 | 15.46 | 21.58 | 19.44 | 9.67 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 0.6 | 0.67 | 0.67 | 0.68 | 0.69 | |||||
Fixed Assets Turnover | 8 | 9.88 | 7.66 | 5.02 | 5.03 | |||||
Receivables Turnover (Average Receivables) | 6.62 | 5.56 | 4.78 | 5.13 | 4.91 | |||||
Inventory Turnover (Average Inventory) | 11.71 | 14.85 | 16.48 | 15.99 | 0.82 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 3.96 | 2.7 | 2.45 | 3.4 | 3.39 | |||||
Quick Ratio | 3.65 | 2.49 | 2.25 | 3.06 | 2.92 | |||||
Operating Cash Flow to Current Liabilities | 1.04 | 0.63 | 0.6 | 1.17 | 1.05 | |||||
Days Sales Outstanding (Average Receivables) | 55.16 | 65.65 | 76.33 | 71.36 | 74.38 | |||||
Days Outstanding Inventory (Average Inventory) | 31.18 | 24.58 | 22.15 | 22.89 | 442.76 | |||||
Average Days Payable Outstanding | 48.1 | 47.44 | 52.9 | 56.78 | 2.25T | |||||
Cash Conversion Cycle (Average Days) | 38.24 | 42.79 | 45.59 | 37.47 | -1.73T | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 33.25 | 16.41 | 20.63 | 19.14 | 12.77 | |||||
Total Debt / Total Capital | 24.95 | 14.1 | 17.1 | 16.07 | 11.32 | |||||
LT Debt/Equity | 32.05 | 5.47 | 11.57 | 17.57 | 12.77 | |||||
Long-Term Debt / Total Capital | 24.05 | 4.7 | 9.59 | 14.75 | 11.32 | |||||
Total Liabilities / Total Assets | 33.7 | 27.9 | 31.35 | 30.36 | 29.76 | |||||
EBIT / Interest Expense | 8.05 | 35.07 | 85.83 | - | - | |||||
EBITDA / Interest Expense | 9.07 | 39.56 | 94.02 | - | - | |||||
(EBITDA - Capex) / Interest Expense | 8.16 | 37.24 | 87.87 | - | - | |||||
Total Debt / EBITDA | 1.95 | 1 | 1.06 | 0.76 | 0.57 | |||||
Net Debt / EBITDA | -1.09 | -2.52 | -1.32 | -0.89 | -1.46 | |||||
Total Debt / (EBITDA - Capex) | 2.17 | 1.06 | 1.14 | 0.81 | 0.6 | |||||
Net Debt / (EBITDA - Capex) | -1.21 | -2.68 | -1.41 | -0.95 | -1.53 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | 8.38 | 31.34 | 26.76 | 24.81 | 21.45 | |||||
Gross Profit, 1 Yr. Growth % | 3.98 | 26.62 | 28.02 | 24 | 76.61 | |||||
EBITDA, 1 Yr. Growth % | -34.93 | 20.99 | 57.26 | 46.62 | 9.26 | |||||
EBITA, 1 Yr. Growth % | -36.55 | 20.07 | 59.64 | 47.28 | 9.21 | |||||
EBIT, 1 Yr. Growth % | -36.55 | 19.83 | 58.55 | 47.67 | 9.18 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | -78 | 72.43 | 61.62 | 36.68 | 40.23 | |||||
Net Income, 1 Yr. Growth % | -78 | 72.43 | 61.62 | 36.68 | 40.23 | |||||
Normalized Net Income, 1 Yr. Growth % | -39.54 | 36.22 | 76.85 | 50.58 | 7.83 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | -77.88 | 69.57 | 58.33 | 33.2 | 41.95 | |||||
Accounts Receivable, 1 Yr. Growth % | 18.08 | 88.68 | 25.51 | 9.06 | 43.35 | |||||
Inventory, 1 Yr. Growth % | 8.93 | 15.08 | 9.12 | 49.87 | 20.21 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | 22.29 | -6.55 | 138.53 | 70.46 | -7.91 | |||||
Total Assets, 1 Yr. Growth % | 19.47 | 14.29 | 37.27 | 14.37 | 24.55 | |||||
Tangible Book Value, 1 Yr. Growth % | 22 | 21.59 | 31.56 | 16.29 | 27.7 | |||||
Common Equity, 1 Yr. Growth % | 22 | 24.29 | 30.69 | 16.03 | 25.62 | |||||
Cash From Operations, 1 Yr. Growth % | 12.25 | 32.32 | 14.88 | 52.71 | 31.46 | |||||
Capital Expenditures, 1 Yr. Growth % | 114.68 | -29.49 | 71.52 | 34.98 | -10.99 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | -10.53 | -14.59 | 65.75 | 4.26 | -39.62 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | -10.66 | -12.98 | 64.46 | 4.26 | -39.62 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | 19.93 | 19.3 | 29.03 | 25.78 | 23.12 | |||||
Gross Profit, 2 Yr. CAGR % | 16.72 | 14.74 | 27.32 | 26 | 47.98 | |||||
EBITDA, 2 Yr. CAGR % | -3.32 | -11.27 | 37.94 | 51.85 | 26.57 | |||||
EBITA, 2 Yr. CAGR % | -4.24 | -12.72 | 38.45 | 53.33 | 26.82 | |||||
EBIT, 2 Yr. CAGR % | -4.24 | -12.8 | 37.84 | 53.02 | 26.97 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | 55.62 | -38.41 | 66.94 | 48.63 | 38.44 | |||||
Net Income, 2 Yr. CAGR % | 55.62 | -38.41 | 66.94 | 48.63 | 38.44 | |||||
Normalized Net Income, 2 Yr. CAGR % | -6.78 | -9.25 | 55.21 | 63.19 | 27.43 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | 53.59 | -38.76 | 63.85 | 45.22 | 37.5 | |||||
Accounts Receivable, 2 Yr. CAGR % | 21.05 | 49.26 | 53.89 | 17 | 25.04 | |||||
Inventory, 2 Yr. CAGR % | 32.78 | 11.96 | 12.06 | 27.88 | 34.22 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | 15.79 | 6.9 | 49.3 | 101.64 | 25.29 | |||||
Total Assets, 2 Yr. CAGR % | 25.97 | 16.85 | 25.25 | 25.3 | 19.35 | |||||
Tangible Book Value, 2 Yr. CAGR % | 46.88 | 21.79 | 26.27 | 23.69 | 21.86 | |||||
Common Equity, 2 Yr. CAGR % | 46.88 | 23.14 | 27.45 | 23.14 | 20.73 | |||||
Cash From Operations, 2 Yr. CAGR % | 32.09 | 21.87 | 23.29 | 32.45 | 41.68 | |||||
Capital Expenditures, 2 Yr. CAGR % | 26.17 | 23.04 | 9.97 | 52.16 | 9.61 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | 10.39 | -9.73 | 23.46 | 36 | -20.66 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | 10.21 | -8.95 | 24.07 | 36 | -20.66 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | 35.94 | 23.62 | 21.74 | 27.61 | 24.32 | |||||
Gross Profit, 3 Yr. CAGR % | 39.65 | 19.93 | 19.01 | 26.2 | 41.01 | |||||
EBITDA, 3 Yr. CAGR % | 68.64 | 4.18 | 7.38 | 40.77 | 36.07 | |||||
EBITA, 3 Yr. CAGR % | 70.94 | 3.26 | 6.74 | 41.33 | 36.93 | |||||
EBIT, 3 Yr. CAGR % | 70.94 | 3.19 | 6.43 | 41.04 | 36.73 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | 61.94 | 61.03 | -15.05 | 56.17 | 45.77 | |||||
Net Income, 3 Yr. CAGR % | 61.94 | 61.03 | -15.05 | 56.17 | 45.77 | |||||
Normalized Net Income, 3 Yr. CAGR % | 91.16 | 5.79 | 13.36 | 53.65 | 42.14 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | 61.11 | 58.74 | -15.95 | 52.92 | 44.12 | |||||
Accounts Receivable, 3 Yr. CAGR % | 47.84 | 40.35 | 40.88 | 37.2 | 25.2 | |||||
Inventory, 3 Yr. CAGR % | 41.07 | 26.6 | 11.01 | 23.46 | 25.27 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 66.31 | 7.81 | 39.69 | 56.05 | 55.29 | |||||
Total Assets, 3 Yr. CAGR % | 27.79 | 21.95 | 23.3 | 21.52 | 25.05 | |||||
Tangible Book Value, 3 Yr. CAGR % | 41.91 | 37.91 | 24.83 | 22.85 | 25.01 | |||||
Common Equity, 3 Yr. CAGR % | 41.91 | 38.93 | 25.61 | 23.52 | 23.96 | |||||
Cash From Operations, 3 Yr. CAGR % | 36.25 | 32.17 | 19.5 | 32.41 | 32.12 | |||||
Capital Expenditures, 3 Yr. CAGR % | -1.92 | 3.93 | 37.44 | 17.75 | 27.25 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | 71.9 | 3.53 | 13.29 | 19.89 | 3.75 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | 71.44 | 4.07 | 13.61 | 20.07 | 3.75 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | 137.5 | 55.9 | 33.13 | 24.48 | 22.29 | |||||
Gross Profit, 5 Yr. CAGR % | 106.83 | 70.98 | 34.58 | 22.32 | 29.85 | |||||
EBITDA, 5 Yr. CAGR % | 8.43 | 21.74 | 55.61 | 21.13 | 14.68 | |||||
EBITA, 5 Yr. CAGR % | 7.11 | 19.74 | 57.12 | 20.95 | 14.36 | |||||
EBIT, 5 Yr. CAGR % | 7.11 | 19.69 | 56.84 | 20.8 | 14.21 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | -8.68 | 1.62 | 63.92 | 55.95 | 3.28 | |||||
Net Income, 5 Yr. CAGR % | -8.68 | 1.62 | 63.92 | 55.95 | 3.28 | |||||
Normalized Net Income, 5 Yr. CAGR % | 6.2 | 17.6 | 75.87 | 25.81 | 18.79 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | -10.81 | -0.75 | 62.2 | 53.19 | 2.34 | |||||
Accounts Receivable, 5 Yr. CAGR % | - | 62.25 | 50.23 | 30.5 | 34.32 | |||||
Inventory, 5 Yr. CAGR % | - | 102.77 | 28.66 | 27.11 | 19.77 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | 90.13 | 68.21 | 59.29 | 38.49 | 33.74 | |||||
Total Assets, 5 Yr. CAGR % | 41.52 | 23.71 | 26.77 | 23.28 | 21.7 | |||||
Tangible Book Value, 5 Yr. CAGR % | 34.27 | 35.03 | 35.43 | 31.95 | 23.63 | |||||
Common Equity, 5 Yr. CAGR % | 34.27 | 35.63 | 35.94 | 32.38 | 23.63 | |||||
Cash From Operations, 5 Yr. CAGR % | 19.29 | 29.18 | 30.91 | 32.28 | 27.92 | |||||
Capital Expenditures, 5 Yr. CAGR % | 41.62 | 18.91 | 2.68 | 21.05 | 25.55 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | 33.04 | 43.22 | 52.53 | 17.49 | 9.14 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | 32.91 | 43.94 | 52.59 | 17.53 | 6.79 |
- Stock Market
- Equities
- NBIX Stock
- Financials Neurocrine Biosciences, Inc.
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















